Tetraglycine hydroperiodide is an iodine-containing chemical, used for water purification. Tetraglycine hydroperiodide is marketed in tablets; each tablet effectively disinfects 1 liter of clear water or 0.5 liter of tainted water by releasing approximately 8 mg free iodine. It requires approximately 30 minutes to inactivate target microorganisms and make water bacteriologically suitable for drinking. To remove iodine taste, a vitamin C pill is added to the kit.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The susceptibility of the fetus and child to chemical pollutants. Special susceptibility of the host to chemical agents: endocrinologic considerations. | 1974 May |
|
Thyroid adaptation to chronic tetraglycine hydroperiodide water purification tablet use. | 1995 Jan |
|
Case report: reversible mitral regurgitation and congestive heart failure complicating thyrotoxicosis. | 1996 Mar |
|
Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies. | 1997 Jul |
|
Adverse reactions to nonionic iodine in contrast-enhanced computed tomography: usefulness of monitoring vital signs. | 1998 Jul |
|
Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy. | 1999 Sep-Oct |
|
Anti-goitrous effect of lecithin-bound iodine in propylthiouracil treated rats. | 2000 Jun |
|
Effects of iodine on inducible nitric oxide synthase and cyclooxygenase-2 expression in sulfur mustard-induced skin. | 2001 Feb |
|
Effects of selenium and iodine on the expression of c-fos and c-jun mRNA and their proteins in cultured rat hippocampus neurons. | 2002 Jun |
|
Effects of selenium and iodine on c-fos and c-jun mRNA and their protein expressions in cultured rat hippocampus cells. | 2002 Winter |
|
Synergistic interaction between excess caffeine and deficient iodine on the promotion of thyroid carcinogenesis in rats pretreated with N-bis(2-hydroxypropyl)nitrosamine. | 2003 Apr |
|
Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. | 2003 Jan |
|
Thiocyanate induces cell necrosis and fibrosis in selenium- and iodine-deficient rat thyroids: a potential experimental model for myxedematous endemic cretinism in central Africa. | 2004 Feb |
|
Studies on experimental iodine allergy: 3. Low molecular weight elicitogenic antigens of iodine allergy. | 2004 May |
|
[Effect of high-iodine intake on MBP mRNA expression in cerebrum of filial mice and selenium intervention]. | 2005 Jul |
|
Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. | 2005 May 31 |
|
Involvement of tumor necrosis factor-alpha in sulfur mustard-induced skin lesion; effect of topical iodine. | 2005 Nov |
|
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. | 2005 Oct |
|
Effect of selenium supplementation on activity and mRNA expression of type 1 deiodinase in mice with excessive iodine intake. | 2006 Aug |
|
Synergistic regulation of endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid (GLA) via Claudin-5 modulation. | 2006 Aug 1 |
|
Salt dual-fortified with iodine and micronized ground ferric pyrophosphate affects iron status but not hemoglobin in children in Cote d'Ivoire. | 2006 Jul |
|
Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. | 2006 Jul 14 |
|
The loss of the chloride channel, ClC-5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland. | 2006 Mar |
|
Antiseptics, iodine, povidone iodine and traumatic wound cleansing. | 2006 Nov |
|
Comparative cytotoxicity of high-osmolar and low-osmolar contrast media on HKCs in vitro. | 2006 Nov-Dec |
|
The treatment of Graves' disease in children. | 2006 Sep |
|
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. | 2007 Apr |
|
Goiter and other iodine deficiency disorders: A systematic review of epidemiological studies to deconstruct the complex web. | 2007 Jan |
|
[Effects of iodine excess and selenium supplement on the levels of thyroid hormone and its receptor expression in filial cerebrum of mice]. | 2007 Mar |
|
Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment. | 2007 Mar |
|
Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). | 2007 Nov |
|
Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. | 2007 Oct 1 |
|
[Suggestions for prevention of adverse reactions after intravasal administration of iodinated contrast media]. | 2008 |
|
[The effects of iodine/selenium on the function of antigen presentation of peritoneal macrophages in rats]. | 2008 Jul |
|
Gadolinium and kidney disease: are your patients at risk? | 2008 Mar-Apr |
|
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. | 2009 Dec |
|
A blinded, randomized, palatability study comparing variations of 2 popular field water disinfection tablets. | 2011 Dec |
|
I-131 dose response for incident thyroid cancers in Ukraine related to the Chornobyl accident. | 2011 Jul |
|
The effects of ammonium perchlorate on thyroid homeostasis and thyroid-specific gene expression in rat. | 2012 Aug |
|
Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice. | 2012 Sep 1 |
|
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. | 2013 Jan |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG51AD01
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-VATC |
QD08AG02
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
NDF-RT |
N0000007196
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-ATC |
G01AX11
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
WHO-VATC |
QD11AC06
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-ATC |
S01AX18
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
FDA ORPHAN DRUG |
564916
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
WHO-ATC |
R02AA15
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
FDA ORPHAN DRUG |
566216
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
WHO-ATC |
D11AC06
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
NDF-RT |
N0000175486
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-ATC |
D08AG02
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-VATC |
QS01AX18
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
CFR |
21 CFR 333.210
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
FDA ORPHAN DRUG |
647518
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
WHO-VATC |
QG01AX11
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-VATC |
QD09AA09
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
||
|
WHO-ATC |
D09AA09
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
EPA PESTICIDE CODE |
46914
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
||
|
WHO-VATC |
QR02AA15
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
85H0HZU99M
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
26245
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | |||
|
DTXSID8035712
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201724
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
POVIDONE-IODINE
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | |||
|
Povidone-Iodine
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
4249
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
m9085
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB06812
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
C766
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | |||
|
6831
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
D011206
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | |||
|
8611
Created by
admin on Fri Dec 15 16:00:47 GMT 2023 , Edited by admin on Fri Dec 15 16:00:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
85H0HZU99M
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
SUB14999MIG
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY | |||
|
25655-41-8
Created by
admin on Fri Dec 15 16:00:46 GMT 2023 , Edited by admin on Fri Dec 15 16:00:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD